Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences

NEXT STORY
Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac’s Type A Meeting with FDA on Treosulfan
PREV STORY
Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Norovirus Gastroenteritis Costs an Estimated $10.6 Billion Each Year in the United States

author_avatar
NASDAQ Market News

Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)

author_avatar
NASDAQ Market News

SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors

author_avatar
NASDAQ Market News